Today on the Biorasi Few & Far Between podcast:

Join new host Melissa Alesse and former host Chris O'Brien - CEO at Rancho BioSciences and Biorasi Board member - as they explore the origins and evolution of our podcast and what we've learned along the way.

We dive deep into the importance of long-form media and thought leadership, AI's continuous evolution, and CROs from the CEO's POV.

Watch this episode today!

Today on the Biorasi podcast, we look back on three years of AI innovation in healthcare and clinical trials - breaking new boundaries and a creating a new reality across all industries.

Host Chris O'Brien welcomes back Zak Kohane, AI Oracle and Professor and Chair of Biomedical Informatics at Harvard Medical School. We'll journey back to Zak's first appearance on the podcast and take stock of what three years means to AI development including widespread adoption by patients and physicians, how cancer still outsmarts today's LLMs, and the importance of sharing prompts with fellow AI travellers.

Find answers to the top AI questions in this new episode!

How do today’s CEOs and founders find the balance between planning and entrepreneurship?

Check out the latest episode of the Biorasi Few & Far Between podcast - How Biotech Gets Built. Host Chris O'Brien welcomes Sinan Gölhan, CEO at GelTech Labs. We'll be exploring life in a biotech startup, hydrogels in lab robotics, and bringing AI into your organization.

Watch this episode today!

Let's kick off 2026 with the first Biorasi podcast episode of the year!

How do you get "Biotech Vision" to see the complete picture of your place in the industry?

Find out in the latest episode of the Few & Far Between podcast - How Biotech Gets Built. Host Chris O'Brien welcomes guest Aoife Brennan, President and CEO of Climb Bio. We'll be discussing how to leverage science and strategy, the differences between CEOs and CMOs, and how hiring an "operational penknife" is critical to new organizations.

Watch it today!

Are clinical trial protocols a true art form?

Find out in a new episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes guest Mark Ableson, founder of Ora Clinical and CRO pioneer.

We'll be discussing exploratory endpoints, what to learn from failed trails, and essential factors in choosing a clinical site location.

Listen today!

With biotech, is it the destination, the journey, or both?

Find out in a new episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes guest Amit Etkin, Founder and CEO of Alto Neuroscience and Professor of Psychiatry at Stanford University School of Medicine. We’ll be discussing placebos in psychiatry, using biomarkers for patient outcomes, and what you can and can’t do in academia and biotech.

Watch it today!

Will GLP-1's one day replace our morning coffee?

Find out in a special video episode of the Few & Far Between podcast!

Host Chris O'Brien welcomes friend of the show, Professor Justin Stebbing. In this new segment, we'll spotlight biotech trends that you need to know about - from T cells to GLP-1 - and identify which innovations are worth the hype.

Let's start the podcast!

What if the future of biotech is actually late-stage execution?

Welcome to our first video episode of the Biorasi Few & Far Between podcast with your host, Chris O’Brien. Today, we welcome guest Bruce Leuchter, MD, President and CEO of Neurvati Neurosciences. We’ll be covering a myriad of biotech topics, from “business athletes” to the role of the operating company in the drug development industry. We’ll also be premiering our lightning round - quick questions and inspired answers from our podcast guests.

Okay, let’s start the podcast!